Helsinn Therapeutics offers the Helsinn Cares program that supports access, reimbursement, and assistance for patients prescribed Akynzeo (netupitant and palonosetron) for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV).
Helsinn does not provide financial assistance for Aloxi (palonosetron HCl), which is distributed by Helsinn and by Eisai, but it offers several tools and resources that provide information about CINV, its treatment, and organizations that can offer cancer support.
The approved indications of Helsinn’s 2 oncology supportive care drugs, Akynzeo and Aloxi, can be found in the Table.
Helsinn Cares Services
Helsinn Cares provides several services for patients who have been prescribed Akynzeo.
Akynzeo Pay $0 Savings Program offers eligible patients who have commercial insurance a $0 copay on each prescription, with an $1800 annual limit. For cash-paying patients, Helsinn will pay up to $150 per prescription, for a maximum of $1800 annually.
Akynzeo Quick Start Voucher Program is designed for patients who face delays because of prior authorization requirements for coverage of their Akynzeo prescription from their insurance company. Patients will receive 1 free dose of Akynzeo through this program during the insurance verification process.
Helsinn Cares Patient Assistance Program provides Akynzeo at no cost to uninsured and underinsured patients, as well as Medicare Part D beneficiaries who meet the eligibility requirements.
Reimbursement Support Resources and Patient and Caregiver Access Resources provide support and resources to healthcare professionals, patients, and caregivers for Akynzeo reimbursement, including confirming benefit coverage and facilitating prior authorizations or appeals (HelsinnReimbursement.com).
Akynzeo Pay $0 Savings Program
To be eligible for the Akynzeo Pay $0 Savings Program, patients must have commercial insurance and must:
- Have a prescription for Akynzeo
- Not be enrolled in state or federal healthcare programs, including Medicare, Medicaid, Medigap, VA, DoD, or TRICARE
- Live within the United States.
Eligible patients will have a $0 copay for Akynzeo, with an $1800 annual limit. For cash-paying patients, Helsinn will pay up to $150 per prescription, for an annual maximum of $1800. This offer is available to residents of Massachusetts through June 30, 2019, and expires for all other patients on October 3, 2019.
No activation or enrollment is required for this program. The savings card can be downloaded directly from AkynzeoSavingsProgram.com.
Akynzeo Quick Start Voucher Program
This program is for patients whose insurance company requires prior authorization for Akynzeo. To be assessed for eligibility for the Akynzeo Quick Start Voucher Program, patients must be enrolled in Helsinn Cares. The program is available for all eligible patients with commercial or government-sponsored insurance plans. Through the Akynzeo Quick Start Voucher Program, patients will receive 1 free dose of Akynzeo during the insurance verification period.
Helsinn Cares Patient Assistance Program
To determine eligibility for this program, patients must be enrolled in Helsinn Cares and must also:
- Have a prescription for Akynzeo
- Be a US resident, including Puerto Rico, Guam, and the US Virgin Islands
- Have a mailing address that is not a PO Box
- Be uninsured or underinsured, with no insurance coverage for Akynzeo
- If insured, have had prior authorization and 1 appeal denied (if applicable)
- Meet income criteria with appropriate documentation.
Application & Enrollment
Physicians must enroll their patients in Helsinn Cares to avail them of the Akynzeo Quick Start Voucher Program and Helsinn Cares Patient Assistance Programs, and for this, completion of the Helsinn Cares Patient Support Program Patient Enrollment Form is required.
The form must be filled out in black ink and faxed to 844-357-4669. Financial documentation is required for enrollment in the Helsinn Cares Patient Assistance Program, including a 1040 tax return, SSA-1099, W-2, Social Security benefit statement, unemployment or disability statement, or 1 month of paycheck stubs.
Table Helsinn Oncology Supportive Care Drugs
Prevention of acute, delayed nausea and vomiting associated with moderately emetogenic chemotherapy in adults; prevention of acute nausea and vomiting associated with highly emetogenic chemotherapy in adults; prevention of postoperative nausea and vomiting for up to 24 hours postsurgery in adults
Prevention of acute nausea and vomiting associated with emetogenic chemotherapy in young patients aged 1 month to <17 years